NCT02613949View on ClinicalTrials.gov

Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 202

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 8, 2016

Study Completion Date

July 29, 2016

Conditions
Fibromyalgia
Interventions
DEVICE

RINCE

The NeuroPoint device is used to deliver repeat applications of RINCE therapy

Trial Locations (4)

14221

Upstate Clinical Research Associates, Williamsville

35216

Achieve Clinical Research, LLC, Birmingham

60634

Chicago Research Center, Chicago

95825

Superior Research LLC, Sacramento

Sponsors
All Listed Sponsors
lead

Cerephex Corporation

INDUSTRY

NCT02613949 - Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 202 | Biotech Hunter | Biotech Hunter